Clinical Trial

Safety and Feasibility of Transcatheter Injectable Hydrogel in Acute STEMI Reperfusion Injury (REFINE Study)

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to preliminarily evaluate the safety and feasibility of the transcatheter injectable protein alginate-based hydrogel developed and manufactured by Myomed Technology (Shaoxing) Co., Ltd. in alleviating reperfusion injury in acute STEMI. This is a randomized controlled trial with a blank control group (conventional PCI treatment). A total of 20 patients will be enrolled in a 1:1 ratio into the test group and the control group.
Trial Details
NCT Number NCT07601997
Lead Sponsor Myomed Technology (Shaoxing) Co., Ltd.
Conditions STEMI - ST Elevation Myocardial Infarction
Enrollment 20 participants
Start Date 2026-05-30
Primary Completion 2026-10-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22